bluebird bio (BLUE) Announces FDA Approval of LYFGENIA for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Severe vaso-occlusive events were eliminated for 94% of evaluable patients and all VOEs were eliminated for 88% of evaluable patients between 6 and 18 months post-infusion
LYFGENIA is the most.
bluebird bio Announces FDA Approval of LYFGENIAtm (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
NIH Strives to Safeguard Fertility Amidst Gene Therapy miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Adenosine base editing restarted fetal hemoglobin expression in cells from patients with sickle cell disease. Find how St. Jude & Broad are advancing to a cure.